Illumina, Inc. (NASDAQ:ILMN) Stock Position Raised by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,372 shares of the life sciences company's stock after buying an additional 3,309 shares during the quarter. IFM Investors Pty Ltd's holdings in Illumina were worth $2,568,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Fourth Dimension Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $40,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina in the fourth quarter valued at about $45,000. Assetmark Inc. boosted its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Illumina in the fourth quarter valued at about $48,000. Finally, Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Buying and Selling

In other news, CFO Ankur Dhingra purchased 6,100 shares of the stock in a transaction dated Monday, May 12th. The shares were bought at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer owned 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Barclays reissued an "underweight" rating and issued a $85.00 price target (up previously from $77.00) on shares of Illumina in a report on Tuesday, June 24th. Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target for the company. in a report on Friday. Guggenheim reduced their price target on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. Morgan Stanley reduced their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Finally, Canaccord Genuity Group increased their target price on Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a report on Wednesday, June 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $125.11.

Illumina Stock Performance

ILMN traded down $0.80 during trading hours on Friday, hitting $99.25. The company's stock had a trading volume of 1,998,677 shares, compared to its average volume of 2,151,831. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $15.71 billion, a PE ratio of -16.35, a PEG ratio of 1.96 and a beta of 1.36. The company has a 50-day simple moving average of $86.75 and a 200 day simple moving average of $96.72.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same period last year, the firm earned $0.98 EPS. The firm's revenue was down 1.4% compared to the same quarter last year. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.